- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
You are here
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
Status
Completed
Phase
III
Principal Investigator(s)
Xavier Anglaret & Serge Eholié
Objective
To assess the benefits and risks of early antiretroviral therapy in HIV infected adults in Abidjan, Cote d'Ivoire
Prevention Option(s)
Treatment
Study Design
Controlled
Randomized
Open label
Arms and Assigned Interventions
Description
Standard Care:
Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
Mode of Delivery
Tablet
ARMs
Placebo Comparator
Description
Standard of care+Isoniazid Prophylaxis:
Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.
Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
Mode of Delivery
Tablet
ARMs
Experimental
Description
Early Antiretroviral therapy:
Early ART initiation on the day of inclusion, before reaching the current WHO criteria
Mode of Delivery
Tablet
ARMs
Experimental
Description
Early Antiretroviral therapy + Isoniazid prophylaxis:
Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria
Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion
Mode of Delivery
Tablet
ARMs
Experimental
Official Code
Trial Sponsors
French National Agency for Research on AIDS and Viral Hepatitis
Product Developers
Gilead Sciences & Merck Sharp & Dohme Corp.
March 2008
December 2014
Enrollment
2 073
18
Years
Population
Women
Men
HIV positive
Sites
Centre de Prise en Charge et de Formation ACONDA
Abidjan
Ivory Coast
Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine
Abidjan
Ivory Coast
Centre Intégré de Recherches Biocliniques d'Abidjan
Abidjan
Ivory Coast
Service des Maladies Infectieuses et Tropicales, CHU de Treichville
Abidjan
Ivory Coast
Unité de Soins Ambulatoires et de Conseil, CHU de Treichville
Abidjan
Ivory Coast
Centre de prise en charge de personnes vivant avec le VIH la pierre angulaire
Abidjan
Ivory Coast
Hopital Général Felix Houphouet Boigny
Abidjan
Ivory Coast
Formation Sanitaire Urbaine Anonkoua Kouté
Abidjan
Ivory Coast
Centre médico-social El Rapha
Abidjan
Ivory Coast